Does the risk of death from breast cancer after tamoxifen treatment increase when selective serotonin reuptake inhibitor antidepressants have been co-prescribed?

From: BMJ

Journal rating:
rating: 98%
Study Quality:
rating: 55%

Overall Reliability

Article Quality:
rating: 10%
rating: 50%


  • 2,430 women


  • A population based study among female residents of Ontario, Canada, who were aged 66 years or older and who started tamoxifen treatment between 1 January 1993 and 31 December 2005


  • Of 2,430 women treated with tamoxifen and a single SSRI, 374 died of breast cancer during follow up.
  • Use of paroxetine during tamoxifen treatment is associated with an increased subsequent risk of death due to breast cancer in a fashion that correlates with the duration of combined use. By contrast, no such risk was seen with other antidepressants.


  • Yes (with confidence)


Editors Notes

  • Breast cancer is the most commonly diagnosed cancer in women worldwide, and it is estimated that 1.5 million new cases will be diagnosed in 2010